BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18266003)

  • 1. Molecular markers of pancreatic cancer: development and clinical relevance.
    Fry LC; Mönkemüller K; Malfertheiner P
    Langenbecks Arch Surg; 2008 Nov; 393(6):883-90. PubMed ID: 18266003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
    Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
    World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular oncology in pancreatic cancer.
    Gansauge S; Gansauge F; Beger HG
    J Mol Med (Berl); 1996 Jun; 74(6):313-20. PubMed ID: 8862512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of pancreatic carcinoma.
    Rosty C; Goggins M
    Hematol Oncol Clin North Am; 2002 Feb; 16(1):37-52. PubMed ID: 12063828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
    Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
    Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9.
    Däbritz J; Preston R; Hänfler J; Oettle H
    Pancreas; 2009 Jul; 38(5):534-41. PubMed ID: 19295453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer.
    Yin X; Kong L; Liu P
    Clin Epigenetics; 2021 May; 13(1):109. PubMed ID: 33980289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer.
    Rah B; Banday MA; Bhat GR; Shah OJ; Jeelani H; Kawoosa F; Yousuf T; Afroze D
    World J Gastroenterol; 2021 Sep; 27(36):6093-6109. PubMed ID: 34629822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool.
    Mulcahy H; Farthing MJ
    Ann Oncol; 1999; 10 Suppl 4():114-7. PubMed ID: 10436800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
    Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
    Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tumour markers, cytogenetics.
    Lamerz R
    Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer.
    Boadas J; Mora J; Urgell E; Puig P; Roca M; Cussó X; Capellà G; Lluís F; Farré A
    Eur J Gastroenterol Hepatol; 2001 Oct; 13(10):1153-9. PubMed ID: 11711770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tumor markers and molecular biological diagnosis in pancreatic cancer.
    Sawabu N; Watanabe H; Yamaguchi Y; Ohtsubo K; Motoo Y
    Pancreas; 2004 Apr; 28(3):263-7. PubMed ID: 15084968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer.
    Urgell E; Puig P; Boadas J; Capellà G; Queraltó JM; Boluda R; Antonijuan A; Farré A; Lluís F; González-Sastre F; Mora J
    Eur J Cancer; 2000 Oct; 36(16):2069-75. PubMed ID: 11044643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer.
    Tascilar M; Caspers E; Sturm PD; Goggins M; Hruban RH; Offerhaus GJ
    Ann Oncol; 1999; 10 Suppl 4():107-10. PubMed ID: 10436798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum.
    Theodor L; Melzer E; Sologov M; Idelman G; Friedman E; Bar-Meir S
    Dig Dis Sci; 1999 Oct; 44(10):2014-9. PubMed ID: 10548352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.
    Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S
    Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
    Chang JC; Kundranda M
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic diagnosis of pancreatic cancer.
    Mizumoto K; Tanaka M
    J Hepatobiliary Pancreat Surg; 2002; 9(1):39-44. PubMed ID: 12021896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.